Home / Transcripts / Nanosonics Limited (NAN) · November 4, 2026

Nanosonics Limited (NAN) Earnings Call Transcript

November 4, 2026

ASX AU Health Care Health Care Equipment and Supplies shareholder_meeting 86 min

Earnings Call Speaker Segments

Steven Sargent executive
#1

Thank you for that. Good morning, ladies and gentlemen. My name is Steve Sargent, and I'm the Non-Executive Chairman forensics I hope that, that short video gave you a sense of who we are at NAN and what we strive for every day. I would like to extend a warm welcome to our shareholders here at the company's headquarters in Macquarie Park in Sydney. And those joining us online, welcome. It is my privilege to chair this 20th Annual General Meeting. I would also like to acknowledge the traditional owners of the various lands on which we meet today and pay our respect to all aboriginal elders, past and present, and acknowledge today's aboriginal communities who are custodians of these lands. With me in the room, I'm joined by the Nanosonics Board of Directors our Company Secretary, representatives of the company's auditor, Ernst & Young. I've been advised by the company secretary that we have a quorum for this meeting, and I, therefore, declare the meeting open. The number of valid proxies received by 11:00 a.m. on Monday, the second of November, was 293 proxies representing over 190 million shares or just over 64% of the company's approximately 297 million shares that are issued. I would like to take this opportunity to introduce the Board and the Company Secretary and our auditors representatives. Firstly, Michael Kavanagh, our Managing Director and CEO; Tracey Batten in the middle there; Larry Marshall, on the end; Sarah Butler; Marie McDonald; and Gerard Dalbosco. Down the front, we have our Company Secretary, Matthew Carbines. And as required by the Corporations Act, the company's auditor, Ernst & Young, is also in attendance today represented by Ms. Vida Virgo. Welcome, Vida. Vida oversaw the Nanosonics engagement on behalf of Ernst & Young pertaining to the audit of the full year '26 accounts. The Board, Company Secretary and the company's auditor are available to respond to any questions you may have during the meeting. Also present are members of our management team, who Michael will introduce when he gives his address. Today's meeting will commence with my Chairman's address, and then Michael will then deliver his address. This will be followed by the formal business of the meeting. As this AGM has been conducted in person and online, I will now provide some housekeeping instructions on how to ask questions and how each group shareholders should vote. This is my favorite part. For those shareholders joining online, shareholders can ask questions, which may be written or verbal, Online attendees can submit questions at any time. To ask a question in writing, select the Q&A icon, type your question into the text box. Once you have finished typing, hit the send button. Please note that while you can submit questions from now on, I will not address them until the relevant time in the meeting. Please also note that your questions may be moderated or amalgamated if we receive multiple questions on the same topic. There is further information contained on the meeting platform under the Q&A tab for the shareholders that wish to ask questions verbally. For those shareholders in the room joining us today, please raise your blue voting card if you wish to ask a question in the ordinary way, and one of our staff will provide you with a microphone for you to use when asking your question. That way, not only the folks in this room can hear you, but folks online can hear you. We will set aside time after each resolution to answer any questions on the resolutions. In accordance with our usual practice, in addition to having an opportunity to ask questions on the resolutions, we will also invite general questions after the formal business. So we'll go through the 8 resolutions will close voting and then we'll go to the general questions. This will avoid questioning mixed with questions received and the resolutions during the formal book business. For those shareholders joining online, while there will be time for voting after I have introduced each resolution, you may submit your votes at any time until I declare the poll closed. There will also be some time to complete your voting after we have addressed any questions that are raised in relation to the resolutions. If you are eligible to vote, once voting opens, press the vote icon and all resolutions will be activated with voting options. There is no need to hit a submit or enter button as the vote is automatically recorded. You will receive a vote confirmation notification on your screen. You can change your vote up to any time up until the time we are voting closed. For those shareholders joining in person, after I call for a vote on each resolution, all persons entitled devote will be given a moment to complete their voting card. And before I move on to the next resolution. Voting will be conducted on each resolution by poll for this purpose. I now declare the poll open. Ladies and gentlemen, it's now my pleasure to deliver my Chairman's address. As you saw in that video, our mission at Nanosonics is infection prevention for life. We work to improve the safety of patients, clinics, their staff and the environment, and we do this by transforming infection prevention through innovative technologies that improve standard of care. Our infection prevention solutions engineer out the viability present in manual processes. And through automation, we deliver consistent, more effective and reliable infection prevention control. We're proud that trophon has helped shape global standards in ultrasound probe reprocessing, while CORIS System has the potential to do the same with endoscope reprocessing. Both technologies are focused on protecting patients and improving the quality of care they receive. Full year '26 was a year of solid performance and important strategic progress for Nanosonics. The core trophon business continued to grow, and the number of patients protected during the year exceeded 31 million. With the launch of trophon3 and trophon2 Plus, we launched more new products last year than in any other year in our history. Additionally, Nanosonics laid the foundations for its phase of growth by advancing CORIS to controlled market release. This progress has positioned Anasonix well to pursue the most significant transformation in its history since the launch of trophon, becoming a multi-platform company and entering its next growth horizon. Our goal is both clear and ambitious. We want to build a broader global infection prevention company with multiple technology platforms. and we're aiming to more than double or even triple the number of patients protected from the risk of infection each year. We are confident we have the expertise and technologies to achieve this ambition. Our confidence comes from our position as experts in the automation of manual health care processes in medical reprocessing and in digitization, which align with the key industry dynamics in the infection prevention space. Technology advancements and expanding clinical applications are driving growth across both ultrasound and Endoscopy. Health care providers are increasingly seeking more effective solutions to reduce the risk of cross-contamination between patients. And these solutions need to be validated and audit ready. Hospital budget pressures and inflation have continued, making purchasing decisions increasingly focused on solutions that can demonstrate risk reduction, workflow efficiency and compliance value. Cybersecurity has risen in importance to become a critical component of social license. Patient data protection is paramount. These trends reinforce the relevance of our focus on patient safety, validated automation and digital traceability and workflow efficiency. We are proud that our technologies both reflect rapidly evolving needs of our customers while also being powerful enough to shape health care standards. In full year '26, Nanosonics delivered continued revenue growth, underpinned by the strength of the trophon franchise and disciplined cost management. Strong cash generation supported ongoing investment in research and development, the advancement of CORIS and returns to shareholders through the completion of an on-market buyback. But we've ended the year with a strong debt-free balance sheet, prodding the financial flexibility to fund our strategic priorities and pursue long-term goals. Having completed a $20 million on-market share buyback last year, we are continuing to return capital to shareholders through a new on-market share buyback of up to $40 million, as we announced in August. The buyback signals both our confidence in the future growth of Nanosonics as well as our recognition that the current share price does not reflect the growth opportunities ahead especially with CORIS. The share price has declined over the last 12 months. And while some of that is due to the broader fall across listed healthcare market, our operational and financial performance reflects dedication of our global team of more than 50 people. And on behalf of the Board, I thank each of them for their contribution and commitment throughout the year. Sustainability remains an important element of our long-term strategy. And in full year '26 we've achieved a significant milestone with a 51% reduction in Scope 1 and Scope 2 emissions, reflecting the full year benefit of initiatives implemented over recent years. Looking over the last 2 years, this reduction has increased to an incredible 80% reduction in both Scope 1, Scope 2. We also strengthened our sustainability foundation by advancing our global climate governance, risk management and reporting capabilities while preparing the business for compliance with Australia's new AASB S2 climate disclosures. During the year, we farewelled Dr. Lisa McIntyre, who stepped down from the Board in November 2025. And on behalf of the Board, I would like to thank Lisa again for her significant contribution to Nanosonics. We were pleased to welcome Sarah Butler as an independent Non-Executive Director in January 2026. She brings extensive health care strategy and growth experience that aligns strongly with the company's priorities and ambitions. Nanosonics is supported by an independent and deeply experienced Board with extensive leadership backgrounds across global care, medical technology, science, innovation, finance and governance. This brings the breadth of expertise required to guide the company through its next phase of growth and value contribution. I would like to thank my fellow directors for their leadership counsel and commitment throughout the year as we've positioned Nanosonics for its next phase of growth. Today, we announced the appointment of Julien Sauvagnargues as an independent nonexecutive Director. Julien brings extensive endoscopy, sterilization and service operations leadership experience to the Nanosonics Board. The last 2 decades of Julien's career was with Olympus Corporation, where he most recently served as President and CEO Americas region for Olympus. Julien is based in the United States, our largest customer market, and we look forward to warmly welcoming him to the Board at the start of December. I would like to express my sincere appreciation to our shareholders for your ongoing confidence and support. We value the trust you place in us and continue growing the business. Nanosonics has strong momentum and clear priorities for 27 to build further value from trophon, launch CORIS and scale the capabilities needed for sustainable growth. These priorities will advance our ambition as a multi-platform infection prevention company to protect more patients and create long-term shareholder value. Thank you for that. Now I'll ask Michael to come up and address the shareholders.

Michael Kavanagh executive
#2

A very good morning, everybody. Thank you very much, Steve, and good morning, and welcome. It's great to see a number of very familiar faces to the AGM here, and thank you for taking the trip out to Macquarie this morning. And for everybody that's online as well, welcome. I'd like to begin, first of all, with a brief look back on FY '26, our last financial year. But I think those results and of themselves. They give us a very strong foundation for what comes next. What I would do then is our focus on 3 priorities for the business. And there to extending the opportunity for trophon, where there's still great opportunity there; the commercialization of CORIS, which is critically important; but on top of that is looking at building Nanosonics into a multi platform leader in automated infection prevention. But before I begin, as Steve said, we've got the majority of the executive team here joining us here this morning. And all here in the front, and I won't name them all out, but I must just say you're looking pretty good today for some seen many of you were to tie in a while. I am very fortunate. We're all very fortunate because we do have a very experienced and dedicated executive team who are all really working together to create value not just for patients and for customers for our shareholders as well. And I do certainly encourage you at the end of proceedings to engage with the teams, they would enjoy that. So looking back on FY '26, I think we delivered -- as a business, we delivered very solid underlying growth, but importantly, disciplined execution across a number of really important operational priorities that we had in the business. The reported revenue for the year was just under $204 million. But it's important to look at that on a constant currency basis because that's what really gives you an indication of the performance of the operational performance of the business. So on a constant currency basis, the revenue increased 6% to $211.5 million, with EBIT, of course, increasing 21% to $21.6 million. And our revenue for the year, I acknowledge was slightly below our target that we had said but the strong gross margin that was delivered and importantly, disciplined cost management in the business over the 12 months that did support very, very strong earnings growth in constant currency terms. The overall trophon placements was over 4,000 of those during the year. And so those placements grew 9%. Our cumulative installed base, which is important, that reached over 39,000 units internationally. And upgrade momentum certainly was particularly strong in North America where the majority of the upgrade opportunity actually resides. At that same time, the revenue, we did continue to invest in R&D, in manufacturing, in our digital capabilities, and of course, the commercialization preparations for CORIS. But we did do all of that whilst helping maintaining OpEx growing at a lower level than overall revenue. And you see we did that by holding OpEx growth to 2%. It is also, I think, see on an annual basis in our results, we always call out the trophon only business as well as the consolidated accounts I think that's quite insightful to give everybody an insight as to the performance of the core franchise and how that's doing as a business. And as you can see, the trophon franchise, it continued to generate very strong profitability and cash flow, which is really important. The reported EBIT was $50.6 million for the year and in constant currency, EBIT was increased actually 16% and to $56.5 million. So we delivered even further operating leverage in that business. So in short, trophon remains a highly profitable engine that gives us the flexibility to fund CORIS, to maintain a debt-free balance sheet and to continue to invest for the long term for growth of our business. But they're just the financials. The financials beyond FY '26 materially also strengthened our strategic position as a business. The trophon3 and trophon2 Plus were launched, and both of those extend our leadership in ultrasound probe reprocessing and creates new upgrade software and connectivity opportunities with that critical massive installed base that's out there today. CORIS during the year... [Technical Difficulty] CORIS provides a validated 18-hour window to reprocess these scopes. And what that provided for that site was much greater operational flexibility as well. Apologies about the video because -- we can try. [Presentation]

Michael Kavanagh executive
#3

Said a lot better than what I tried to articulate, but that was a fantastic opportunity we have over there. So as we did outline in our full year results, this is the launch year for CORIS. Some of the CMR sites continuing. We're learning more, but this is the launch here. Our focus this year is very much on building the broad market awareness, developing the sales pipeline, securing initial customers and our reference sites. I'm pleased to say that just a short few weeks ago, a very successful customer launch for the U.K. and Ireland took place and the sales team are now out actively promoting and building the pipeline. We do expect the second FDA 510(k) determination for expanded scope indication shortly. And this will allow us to begin our planned U.S. activities. Preparations for the official launch are also underway here in Australia. CORIS will feature next week at the LIPC conference, the Large Infection Prevention Conference taking place up in Queensland. And in parallel, our clinical program continues to progress, and we do expect a number of further publications this year that will add further evidence of the technology's clinical performance. So a great deal happening around cars and we're definitely making good progress against the plans that we have set. There's still definitely work ahead, but this progress that we are seeing the sort of customer feedback and that's similar in all of them. what you saw today is that we do believe that the gives us real confidence on the future success opportunity. I will say also that I'm delighted to share that CORIS has very recently been also awarded Gold at the Australian Good Design Awards in the medical and scientific category. These awards are -- have recognized excellence in design, in innovation since back in 1958 and with entries assessed independently by a panel of experts. And the jury described CORIS as a highly innovative solution for a complex hygiene challenge. So we were very, very proud to receive that. on behalf of all of our shareholders, but also for all the teams here that have been working on it for many, many years. So finally, I'd like to close with 3 messages. First, trophon certainly remains a growing cash generative platform with significant ongoing growth opportunity from new installed base, upgrades, consumables, service connectivity and geographic expansion. Second, CORIS addresses a large unmet need and gives us the potential to establish a second global platform with highly attractive recurring economics. And third, we have built the capabilities as an organization to develop, manufacture, commercialize and support these but further new platforms at scale. So our priorities are, therefore, quite clear. We need to grow and modernize the trophon installed base. We need to execute and commercialize the rollout of CORIS and then invest selectively in opportunities where we see both a strong clinical need and a compelling commercial case for platform expansion. And we have the financial capacity the infrastructure and experience to pursue this strategy. So I would like to take the opportunity to thank the whole Nanosonics team globally, but also thank you, our shareholders, for your trust, your support. And your belief in the future of the company. Thank you.

Steven Sargent executive
#4

Thank you, Michael. I appreciate that. We'll now move to the formal business of the meeting. The notice of this meeting was circulated to shareholders, and copies are available at the registration desk and on the Nanosonics website. So I propose that the notice be taken as read. I will now outline the procedure for this part of the meeting. Prior to calls for a vote on each resolution, the resolution proxy votes will be shown on screen. I will invite questions and comments on each of the resolutions once the resolutions have been presented. For shareholders who are online, you may either cast your vote at the time of the resolution is read or complete voting on all resolutions after I have read through all the resolutions.and we have concluded answering questions on each of them. I will then provide a warning that the poll is about to close. For those shareholders in the room, I have the following specific instructions. Please use your blue voting cards. After I call for a vote on each resolution or persons entitled to vote will be given a moment to complete their voting card before I move on to the next resolution. On the reverse of your blue voting card is your voting paper and instructions. For proxy holders, you need to mark a box beside the motion to indicate how you wish to cast your open votes or any votes you are entitled to cast. For shareholders, you need to mark a box beside the motion to indicate how you wish to cast your votes. Once we have completed all the resolutions, a representative from Computershare will then come around and collect your completed voting cards. If you require any assistance during the process, please raise your hand and a Computershare representative will come to assist you. As Chairman, I have been given a number of undirected proxies, and I will vote these in favor of each resolution in the poll. The persons entitled to vote on the poll are all shareholders, representatives and attorneys of shareholders and for those in the room, proxy holders who hold blue voting cards. For those shareholders joining online questions may be submitted at any time while the resolutions have been read using the functionality that I've previously described. Questions will be considered and answered for each resolution when the resolution has been read However, there will be a pause at the end to ensure that all shareholders afford the opportunity to ask questions on the resolutions. I'll now turn to the first item of ordinary business, which is to receive and consider the company's reports for the year ended 30 June 2026. No formal vote is required on this item of business, and I would like to now pause for a few months to invite any questions from shareholders. We'll go to the room first, then verbal second and then written, third. There are no questions for that. So we'll note that. Resolution 1 concerns the election of a Director, Ms. Sarah Butler. Ms. Butler was first appointed to the Board earlier this year in 2026, and this resolution seeks shareholder vote on her appointment. Ms. Butler's election was unanimously supported by the Board. I would like to invite Sarah to come up and say a few words, and then we'll take any questions on Sarah's vote. Sarah?

Sarah Butler executive
#5

Thank you, Chairman, and good morning, fellow directors, shareholders, colleagues and guests. I have the privilege of joining on Nanosonics Board and its Innovation and Development Committee in January this year. Today, I'm seeking your support for my election as an independent Non-Executive Director. I also serve on the Board of Australian Clinical Labs, the George statue Global Health, a health tech SaaS company, Lumenis, and ImatheIAG-RECB insurance joint venture. I'm a strategic adviser as well across the broader health sector in the region and in our joint professor of you and stops faculty of Medicine and Health. So I bring to the Board 35 years of global strategic advisory executive and Board experience. After studying Cepestry at the universe of Cambridge, I joined strategy consulting firm, Booz Allen Hamilton, which later became Boosting Company and then PwC Strategy end. And over that time, I worked with over 150 organizations in more than 30 countries across Asia Pacific, Europe and the Americas, including 3 years based in the U.K. and 5 years in China, working all across the Asia region. So more than 50 of these clients were med tech, health providers, insurers pharma diagnostics companies and governments, and I advise them on a range of topics, including reimagining the future of health, growth strategy, digital and AI, people and culture and partnerships. I also had 20 years of executive leadership, delivering better customer outcomes, profitable growth of 20% a year and improved diversity and inclusion, led PwC's $2 billion global health services practice and its New South Wales government practice through COVID-19. And earlier I was Boson Companies, a global insurance leader for 10 years and doubled the China business as Managing Director. I've also been a Board Director for 10 years and shared Board Committees on strategy and ventures, people and remuneration and audit and risk, and this includes governing through significant transformation. So strategy refreshes global growth, a pivot to agentic AI, M&A and leadership transitions. I kept pace with areas like technology innovation, recently coaltar White Paper on the genetic AI governance. So as we heard from Steve and Michael, Nanosonics is at a really exciting stage, becoming a multi-platform company and entering its next horizon of growth. really strong foundation of purpose, customers, products, people and potential and supported by a differentiated capability system from R&D through commercialization. So I believe my experience in strategy, go-to-market, profitable growth into new markets, innovation, SaaS AI and partnerships underpinned by really strong people, financial and risk management can help the company successfully scale new infection in technologies. So like the company, I measure our success by the number of people we protect from infection. And if elected, I look forward to continuing to work alongside my Board colleagues and our experienced management team to deliver great outcomes for our shareholders, our customers, our employees and our communities. So thank you very much.

Steven Sargent executive
#6

Thank you very much, Sarah. She's been contributing on the board for almost 12 months now, and I can assure you, it's been -- we're very, very fortunate to have her. You can see the the results of resolution on screen. Are there any questions in the room? No, but we have a question online.

Matthew Carbines executive
#7

We have a question online for Sarah, which is, what do you see as your key duties as a director?

Sarah Butler executive
#8

I think clearly as the director, you're in a kind of uniquely privileged position to help support kind of the aspirations and success for the organization. And as mentioned, sort of delivering for all our different stakeholders and communities kind of. So that includes all our shareholders who are in the room and on the phone as well as our customers, communities, employees and broader kind of partners and stakeholders more broadly. So fiduciary duty to the organization and really being part of helping enable kind of the success of the organization.

Steven Sargent executive
#9

Thank you, Sarah. I appreciate that. There's no more questions. We will move on to the next resolution. Resolution 2 concerns the reelection of a Director, Dr. Larry Marshall. Dr. Marshall was first appointed to the Board in October 2023. He was appointed Chair of the Innovation and Development Committee in November 2025. And resolution seeks shareholder approval for his reappointment, Dr. Marshall's election is unanimously supported by the Board. I would now like to invite Larry to come up and say a few words.

Larry Marshall executive
#10

Thank you, Chair, and thank you, Board. Thank you, shareholders. Not quite unanimous. I actually didn't vote for myself. I'm humbled to be considered for reelection to this extraordinary company. Nanosonics is fairly unique in Australia. There are many great Australian inventions, but very few of them turn into globally successful companies. Unfortunately, our innovation is nowhere near as good as our invention. And Nanosonics is further unique because it's created now 2 amazing inventions and turn them into real-world products, and they're both new-to-world innovations. Nanosonics in a very real way, created a whole new market vertical for infection prevention, a whole new category of products. that simply didn't exist before Nanosonics created it. That's very rare in this country. But what I'm even prouder of is that every single one of us from the Board, to the management team, to the people that work in the company and to the shareholders. We're all focused on using technology to protect and save lives. And in an age where technology seems hell bent on replacing humans. Isn't it fantastic to work in a company or work with a company that's focused entirely on protecting humans on saving their lives and making their lives better. Thank you so much for consideration of my reelection. I'm really humbled and proud to serve you.

Steven Sargent executive
#11

Thank you very much, Larry. Really appreciate it. Are there any questions with regard to this resolution? In the room? None online? We have one online.

Matthew Carbines executive
#12

We have a question for Dr. Marshall. What does Larry regard as the 2 best decisions the Board has made during his time as a Director. And if he had his time again, would we have done anything different?

Larry Marshall executive
#13

And one of them is appointing you. Look, I've spent most of my life learning by mistakes. So my errors are part of discussion than my correct decisions. But look, the process of turning ideas into real products and actually successfully crossing the valley of death, it's very, very hard. 90% of things fail. I think the key to this Board is there's extraordinary diversity around the table. We never entirely agree on everything. In fact, we often interrogate things very robustly before we make a decision but that is the secret of getting to the right decision. Launching CORIS, absolutely. And another decision that I can't share with you yet but I think you're going to love the outcome, I think that will be the other great decision. Thank you.

Steven Sargent executive
#14

Thank you for that, Larry. Appreciate it. You can see the results on there, and we'll now move to the next resolution. Resolution 3 is for the reelection of Dr. Tracey Batten. Dr. Batten was first appointed to the Board in September 2023. This resolution seeks shareholder approval for her appointment -- reappointment I should say. Dr. Batten's election is unanimously supported by the Board. And I would like to invite Tracey to come up and say a few words.

Tracey Batten executive
#15

Thanks very much, Chairman, and good afternoon now, everyone. Thanks very much for joining us here today. I'm Tracey Batten, and today, I'm seeking your support for my reelection as an independent Non-Executive Director of Nanosonics. Like many of you, I'm a shareholder of Nanosonics and inspired by its mission to transform infection prevention. Over the past 3 years on the Board, I've served on the Audit and Risk Committee and on the Innovation and Development Committee. My career spans more than 30 years of working in the health care sector, primarily in Australia but also internationally. Having initially trained and worked as a medical practitioner transition relatively early in my career into health care management, supplementing my clinical training with a number of management and governance qualifications, including an MBA from Harvard and a fellowship of the Australasian Institute of Company Directors. During my senior executive career, I spent over 15 years as a Chief Executive of a number of large hospital groups including San Vincente, Health Australia here based in Sydney and Imperial College Healthcare NHS Trust based in London. These experiences gave me significant strategic, operational and commercial expertise and considerable skills working with clinicians to deliver high-quality patient care, medical research and its translation into clinical practice with central to these hospitals, continuously improving health outcomes for their patients. For the past 9 years, I've served as a Nonexecutive Director on companies in both Australia and New Zealand. My current directorships include Medibank Private Limited, which is Australia's largest private health insurer; EBOS Group Limited, which is the largest and most diversified Australasian wholesaler distributor of health care, medical and pharmaceutical products; and I've recently joined the Board of IHH Healthcare Para, which is a large multinational private health care group headquartered in Malaysia and in Singapore, operating 89 hospitals and 190 health care facilities around the world. My health care industry knowledge, my expertise gained as a senior executive and CEO working in hospitals and my governance skills gained serving on a diversity of boards, the capabilities that I bring to the Board of Nanosonics. As you've heard, Nanosonics is entering a really exciting phase of its history then delivering a proven trophon product to becoming a multi-platform leader in automated infection prevention with the launch of CORIS. This is something I'm really passionate about, and I believe Nanosonics is really well positioned to continue to set new benchmarks for infection prevention standards. With your support, it would be a privilege to continue to serve you as an independent Nonexecutive Director and to work with my Board colleagues and our experienced management team to continue to drive innovation and growth and Nanosonics. Thanks very much for your support.

Steven Sargent executive
#16

Thank you very much, Tracey. Again, Tracy has been a tremendous contributor over the last 3 years and really appreciate that. Do we have any questions on this resolution? None. Online? Right. And you can see the results there. We'll move to the next resolution, which is the remuneration report. For Resolution 4, the remuneration report, is required to be considered for adoption in accordance with the Corporations Act. The remuneration report forms part of the directors' report and peers on Pages 36 to 59 in our annual report. The vote on this resolution is advisory only and nonbinding. The resolution gives members the opportunity to ask questions or make comments concerning the remuneration report during the meeting. The Chairman of the meeting, other directors and other key management personnel or any other closely related parties will not be included in the votes for this resolution, where in my capacity as Chairman, I'm holding undirected proxies and the appointer has authorized the Chair to vote undirected proxies on this resolution, I will be voting in favor for -- the resolution and the proxies received are now on the screen, let's say, sort of 94% for. Are there any questions folks may have on the remuneration report. Anything online? Thank you. We'll move to the next resolution, which is Resolution 5 Resolution 5 concerns the issue of 70,833 service rights to the Chief Executive Officer and President, Michael Kavanagh, under the full year 26 short-term incentive. The resolution and the proxies received for Resolution 5 are on the screen, the results there. Are there any questions on Resolution 5? It doesn't look like there's any in the room and nothing online. You can see that was voted for. We'll now move to Resolution 6 concerns the issue of 625,363 performance rights to the Chief Executive Officer and President, Michael Kavanagh, under the full year '27 long-term incentive award. The resolution and the proxies received for the resolution are shown on the screen, and similar support as we can see. Are there any questions on the long term? Great. So we've got 2 questions in the room. We'll go to the gentleman on the pent side here first.

Unknown Shareholder shareholder
#17

[ Peter Brandon ], Chairman, shareholder. My question is that the short-term incentives are 12 months performance. And then we've got the long term, which I understand is a 3-year performance. Is that a roll in 3 years? So if it's a rolling 3 years or even said 3 years, aren't you double counting the performance review and therefore, you're just doubling up on the performance rights as well?

Steven Sargent executive
#18

Okay. Thanks for your question. It is a set 3 years. So for the short term incentive, just like I think every other listed company on the ASX, and I throw the New York Stock Exchange and NASDAQ all listed companies from my experience. You have a short-term incentive based upon objectives that the team can or won't meet during the year. So they're very specific objectives over 3 years. For the long-term incentive, there's usually a market measure. So how has the stock performed vis-a-vis a comparative group of companies or -- and then there's typically a long term, in our case, EPS CAGR. So how long is -- are we growing earnings per share over that 3-year period. So it's very standard. -- different measures. You're not -- you have...

Unknown Shareholder shareholder
#19

Okay. I understand that criteria is different for each...

Steven Sargent executive
#20

Exactly. One focused on immediate short-term objectives for this year, the others focused on ensuring long-term growth. And there are different measures within each. Sir?

Unknown Shareholder shareholder
#21

Chairman, my name is [ Peter Dimelo ], I had a long suffering shareholder. For this grant, what's the hurdle rates you have used, A, is there a share price performance because in NASDAQ, you spoke about NASDAQ normally grants over a certain -- in other words, the best 0. So what's the share price? Mark has got the numbers in front.

Unknown Executive executive
#22

There are 2 thoughts for the term -- well, sorry, I'll start again. There are 2 metrics for the long-term incentive. There's relative to one which is measured against the ASX 300, excluding energy, financial mining resources and REITs stocks, so companies that are quite different to us. That's seized for the roof and the EPS CAGR is set against one going forward will be set against last year's earnings per share.

Steven Sargent executive
#23

And if those -- the point you made is correct, if those hurdles are not met, they don't vest. So there's complete alignment with shareholders. If shareholders wins, benefit management will benefit. Any other questions on the LTI? I think if I can now move to Resolution 7. On Resolution 7 considers the reapproval of the Nanosonics equity plan. This is something the equity plan gets approved every -- or presented to shareholders every 3 years. And now it's -- it was approved by shareholders back in 2023 and now up for renewal again. We've got the results on screen. Are there any questions. No questions online. If I can then move on to Resolution 8. resolution considers the approval of an increase in the maximum aggregate nonexecutive directors' remuneration from $1.2 million to $1.6 million, should be noted that the proposed aggregate remuneration of $1.6 million per financial year ceiling only. And at this date, in the notice of meeting, it is not intended that the full amount of the available pool will be paid to nonexecutive directors. This will also provide us with buffer as we bring on new directors like Julien Sauvagnargues in the United States to bring on someone with his experience there it's the rationale for that. Any questions here? No questions online, and the results are there. So I'm just going to pause for a few moments to provide shareholders with a further opportunity to ask any questions with regard to the resolutions. We'll then once that clean will close the meeting, and we can go to close the poll, then we'll go to more general questions, which I think there may be certainly a few online. So the poll will be closing shortly, you're voting. Before it does, I just want to make sure you've got -- get your blue cards in the room here. Online, complete. In the room here, we've got representatives from Computershare, collecting all this on cards. Thank you. And if online intent is can ensure the vote is submitted. I think we're all good Great. Thank you. So the formal business is now completed, and I declare the poll closed. Results of the poll will be announced to the ASX in due course, probably later on this afternoon. I would now like to invite general questions about the business overall. You can ask the Board, Michael management, Ernst & Young, any questions you may have. We'll start with questions in the room first. Great. So I will start with Michael. I'll come sit down here. Yes. Okay.

Unknown Shareholder shareholder
#24

So you don't mind if I sit down? I would like to start up on Course has potential to open a much larger market that ultrasound probe is traction that to be confirmed this in Q1 today, after the biggest barriers to commercial adoption delay and what evidence should we invest to look for over next 12 months to realize adoption is accelerating?

Michael Kavanagh executive
#25

Great question, Michael, and thank you for that. As I alluded to in my address, there's a lot of activities happening in Nanosonics. We've officially launched it in the U.K. and Ireland. We have preparing for the same year in Australia. The determination of the 510(k) will be an important one, but to keep things off in the United States as well. This financial year, what we've said to the market, as you're well aware, it's the launch year. And when you're launching, you've got to build the pipeline. We want to get some of those early units in and can continue to build reference centers. So the things you'd be looking at is when you start hearing about the initial commercial adoption, first units going in, will internally then be very much looking at the pipeline build and our confidence in the pipeline build as the teams are out there making the markets aware. Certainly, the activity now is ramping up in terms of our presence at all the relevant health care and scientific conferences, it just featured very, very recently in Belgrade at the World Conference at the Congress and infection prevention. We prior to that in Barcelona next week, it's up in Brisbane. So a lot of activities. But for an investor, I'd be looking out that publications coming out regulatory approvals and it should hopefully start seeing some announcements of initial adoption. With that initial adoption, then those sites become reference centers and beachheads for others to either visit as well and gain awareness. So a lot of activity going on.

Unknown Shareholder shareholder
#26

Talking about regulatory to, in my estimation, you apply for a finger on May. And this is quite a while sustain. It seems to be a longer period than the usual for 510k. I hesitate very so to mention anything about America these days. But not happens to be there, -- so I can route -- is the FDA talking to you?

Michael Kavanagh executive
#27

Yes. And there's a very in process you go through with the regulators for a 510(k) de novo or any sort of application. And in that process, there can be a lot of engagement between the company and the FDA where the submissions are made, then there can be initial rounds of questions that come back in, depending on the types of questions that are asked, it's sometimes advisable to organize an actual meeting with the FDA. That takes some time. And there's dialogue that takes place in there. Then based on that dialogue and getting a detailed understanding of their questions, so you're not misinterpreting anything, then you put in answers to those questions that gets submitted and process can keep going where they can come back with further questions. it's a discrete process that we follow. And we've done that with trophon successfully. We've done it with the first 510(k) the de novo, we're following a discrete process. And I know sometimes it's you can try and back calculate from a date of submission to anticipate where we should have an approval by that day. And if there isn't an approval by that date, then market reaction can always err on the side of there must be something wrong. You should see silence as just the process is following. We're following the process. If there was anything material I can tell you my further Board members would be telling remind that we need to inform the market. So we're just following the process, and there certainly is engagement with the FDA.

Unknown Shareholder shareholder
#28

That's right. The de novo approval was given a while ago. Now this first like me, I thought a 510k would be chicken peak compared to that. So maybe I'm wrong.

Michael Kavanagh executive
#29

There's nothing chicken feed about the regulations around medical devices. It's certainly the requirements are certainly less but still the requirements for a 510(k) are quite stringent. And -- so remember that de novo back when it was approved on FDA advisements and that's identified that there's always dialogue with the FDA was for the approval of a single scope the call endoscope was their advice for get that approved then build the number of scopes approved. Hence why you had the first 510(k) and a second 510(k). And within 510(k), the were other elements that we put into the 510(k)s beyond just expansion of indications. There are other elements, and they can attract questions as well. So we feel confident in the direction we're going with the FDA, and we look forward to informing the market when they're starting to inform the market.

Steven Sargent executive
#30

Can I ask you to hold Michael, if you don't mind, and then please, and we'll come back to you.

Unknown Shareholder shareholder
#31

Peter Brandon again. I noticed Mr. Chairman that you'll address and the CEO's address was put on the ASX online at 935 this morning. So as I was in the train, I got a bit paved about that, thinking that shouldn't be your address and the CEO's address come after you've given your address to the shareholders or bothered to turn up or have gone online for a couple of hours? Anyway, I'll just make that statement.

Michael Kavanagh executive
#32

The requirements were obliged to comply with is we had a Board meeting this morning, and the Board has to approve and sign off all the documents that you all see here today. And we've gone through, we had a Board meeting last week. We go through any adjustments, any amendments are all approved by the Board. So we -- our meeting started 8:00 this morning. We approved all the -- everything that was released on the ASX as required. And then we also approved the release of the announcement of the new director in the United States, Julien Sauvagnargues. So it's -- we can't really -- I'm trying to -- I don't think there's any other alternatives just once the Board approves it, which is typically first thing in the morning. just like when we approve half year results or full year results, we approve it gets listed on the AV immediately thereafter overshot.

Steven Sargent executive
#33

We've got a question down the back.

Unknown Shareholder shareholder
#34

Dear Board Chairman, like I preface my question a long suffering shareholders holding it for 5 years and every year, you see the share price coming down and down. The objective is that you do well for your employees, yourself and even the shareholders. Now first, I want to divide my talk into 2 parts, first a comment and second question is what always happens is there is the organic business of the company, and there's the public facing the share price, which is indicative of how you sell the story, how sexy you appear to the shareholders. So my question would be, obviously, our investor group doing that part of the job because I see well qualified doctors, and you have the product within your control. But the second part, selling the story to the market. I know this year, you have earmarked $ 44 million for the share buyback. And I can see the support coming in. However, if you see I think about 7, 8 months back, your share was $5.20, and suddenly it dropped and then you guys got a query from the ASX also, which to which you all replied. So I want to know what are you doing for the share price management? And what happened at that point when the share price overnight fell from and it came to something like $3.

Michael Kavanagh executive
#35

Look, thank you for your question. The share price performance, we have to acknowledge we're all shareholders in this room has been disappointing. And there are many dimensions that drive share prices, some of those dimensions out of our control. And the most important thing that we can do as an organization is to focus on the execution of the improved strategy for our business. When you look at the results of the business, I think last year, there was a pretty solid performance, both financially. I mean you have constant currency EBIT growing over 20%. We had record placements, more placements of trophon units in over 3 years. We had record upgrades. We introduced new innovations in trophon3, trophon2 Plus and there are things that are in our control, and we protect it on more patients. There are the things that are in our control, and that's what we have to focus on and execute. The market can react to many different things. It can react to if there's a 1% miss on a particular metric, then there can be a disproportionate impact on the share prices, you've all seen across the equity markets in general, the degree of volatility that exists. And whilst it's encouraging to see that happening, we need to make sure that does not take away our focus on what is most important. We believe the trophon business, and that's why we pull out the trophon business as a stand-alone business. Last year, you saw EBIT of $56.5 million in the trophon only business, up 16%. So operating leverage continued. So you would say that the share price probably doesn't even reflect the value of the trophon only business. let alone the opportunity that exists in CORIS. And that may be an internal perspective, but the confidence with a $40 million share buyback because we are generating that sort of cash is trying to give a return in that way to investors because at the moment, dividend doesn't make sense because we don't have very many banking credits. So I apologize for the share price performance. But I am dedicated and highly focused, as are the board and as are the rest of the management to be very, very focused on the strategy that we've outlined because we believe that the delivery on all the components of that strategy will be reflected in the share price in the future. And -- but I do appreciate your question.

Steven Sargent executive
#36

I think we can go back to Michael.

Unknown Shareholder shareholder
#37

Thank you. Thank you very much. I was going to ask this question are in a way. But then this morning, the 1 thing where I should go ahead and ask it. Now what to do with this morning with the new the executive. I was highly impressed by over the mast the person of search caliber to come and work in that in selecting the merge of onset is pretty obvious. He was them out or stature. So I want to look on that. Now okay, on it that's very total. The question is this, he's a former well manager of enters the biggest manufacture of flexible escapes in the world or based on the Olympus model and the 510(k) first one, again, I read a notice I have fun things around the world. And all of a sudden, the note from FDA of Monaco. The FDA was clearing that Olympus products need a good is quite extreme that this should they have thing now. And listening to you all this morning, your confidence is you're very high. And I think the very fact that this person accepted the job to work with see is enough set by conference. That's it.

Steven Sargent executive
#38

If I -- thanks, Michael. I'll try and -- because I know we have seen line with another question with regard to appointment of new Director, Julien Sauvagnargues. I'll just take 60 seconds to to help people think about how we go about painting directors. There was a question when I say, well, why did they get announced today? And the simple answer is it takes a long time to find these people. They've got to come to the other side of the world. So the way we think about it is we look at the company's strategy, look at where we're going, what we need to get there. We look at the executive team we have in place. And then we think about what are the capabilities and skills that we need on the board to support that team and hold that team to account and represent our shareholders. One that certainly in our discussions with shareholders over the years, once why don't you have a director based in the United States. And I think that's a bold question. I lived there for best part of nearly 2 decades. Larry lived there for a very similar point of time. I know Tracey lived there for a while and studied there. So we've got a lot of experience in the market. But it is fair to say we're not cut. So our first goal was to find someone in the U.S. Our second goal was to find someone who understood the flexible endoscope market and someone who understood the sterilization of flexible endoscopes. And although it is a bit of trying to find a needle in a stack, we engaged the firm we use against the artfuquestion the time line, we used [ Heidrick & Struggles ], and we had a very, very focused scope. We spoke to a lot of people. But to get to ensure we had the right buying from Julien, Julien came and spent a week out in viewed saw our facilities, saw. Our manufacturing facility saw our laboratories, met with every executive on the team. In fact, today, he's in Indianapolis meeting with our U.S. executive. And so he was doing his due diligence on us as we were doing our due diligence on here. that process then takes a very long period of time to get everything lined up. We're required to do police checks and validation checks of education and all those good things. that are required with the appointment of any executive and certainly any director and those processes take time, too. But I agree with it. I think Julien is going to be a wonderful addition to the Board. We're all very excited to have him. Is there any other question? We've got another question.

Unknown Shareholder shareholder
#39

Yes. I just want to ask a question, and I'm sorry if somebody else wants to ask an important one, but mines important to I'm a biologist and I don't get involved in money. I do, but not to the same extent as everybody -- people who are investors, I sat in a room, not this room, I think, a number of years ago when the trophon was being introduced. And I was quite astounded and quite impressed with the the way it was going to be sterilized. The instruments were going to be put into that box and sterilized and auto and so on. And so I was very impressed. And of course, you've moved on to the CORIS. I'm curious -- it's just a curiosity question, because I'm a biologist, I need to know. The instruments that you are sterilizing, are they usually stainless-steel? Because you would imagine that they should be. It would be the safest thing to use. I'm just hoping that maybe there will be some hard plastics involved some stage of the game because I can see Nanosonics moving ahead to all the other instruments that are being used in surgery. I can see the openings there, and I'm sure you will do it.

Michael Kavanagh executive
#40

Thank you. the endoscopes obviously have a lot of a lot of materials in them, and from teflon to stainless steel to et cetera, a lot of alumina internals of the lumens are actually more Teflon-based. But your point is warranted. And what I mentioned is the sort of guiding principle that we're looking at is there's a lot of medical devices and a lot of different medical a lot of medical instrumentation. And they do have different components, different materials constructs. Our goal is not necessarily dictated to by what material we made from our guiding principle is if they're today there is a significant manual process in the reprocessing. We want to bring automation to that. And I think we've got the internal capabilities from a bioscience chemistry, and engineering perspective, that's irrespective of what the material is, we should be able to manage that.

Steven Sargent executive
#41

Okay. Now I think we can move to questions online. Matt?

Matthew Carbines executive
#42

Thank you, Mr. Chairman. The first question is about CORIS, and it's actually about the TAM or total addressable market for the CEO. And the question is, could you comment on the size of the TAM for CORIS?

Michael Kavanagh executive
#43

Yes. Great question. And the traditionally, the TAM or total addressable market has always been looked at even from a trophon perspective in terms of the number of units of trophon we could sell. I think the way to be thinking about the cars opportunities, not the number of cars, devices that are out there, it's the number of angioscope procedures that are actually conducted. That is the TAM. Our goal is just like we with trophon is we're agnostic of brand, be it at Olympus, Fuji, Pentax, et cetera, over time. We expect to cover all brands like we do with trophon in ultrasound and all types of endoscopes. So I mentioned I put up a figure earlier with the initial target market, which is about a market there's about 16 million in so procedure that is being conducted. So at the moment, that's sort of the TAM figure and it's how well we can penetrate into that particular $ 16 million. I will also make a point that unlike trophon, where there are markets around the world today that do not high-level disaffect -- and -- but we believe that over time, those fundamentals will improve in every market around the world today, endoscopes are reprocessed. So we do believe, over time, that $60 million is a lot higher because CORIS really should be a global opportunity.

Unknown Shareholder shareholder
#44

I've got another question here, which has 3 prongs to it. The first part is about the share price, which I think you've commented on already. Then there are 2 more aspects. One is when will we pay a dividend and how we're going to Japan?

Michael Kavanagh executive
#45

So the dividend, I think I already mentioned that we announced to return provide return to the shareholders with the cash balance that we have the Board determination of doing a buyback. We did $20 million last year, we announced $40 million this year. And I think of that $40 million, we're probably close to $8 million of that already. That makes a lot more sense at the moment because the franking credits, the amount of franking credits that we have today are probably sub 900,000 Obviously, as franking credits, and we start paying more tax, I think last year, we paid about 11% in tax. And as the business becomes more profitable, well then we pay more tax, franking credits will go up, et cetera. So we definitely want to provide returns to our shareholders. And -- but we think the buyback this year will do that. Sorry, the second part, Japan, where we're going. Japan, I did mention very briefly in my interest. As you know, Japan actually is one of those markets where high-level disinfection of ultrasound transducers, irrespective of those transducers are inserted into the body and are not required to be high-level disinfected. So over the years, our big focus in Japan has been how do we get guidelines established to mandate the requirement for high level disinfection. To do that, we've had to conduct local studies in Japan to demonstrate that the degree of contamination is actually real. We have conducted now 3, 4 studies. Every 1 of them showed contamination. They are being presented at the conferences over there to actually some of the data from Japan being presented internationally. The good news is that one of the prominent societies in Japan has established now a subcommittee for the establishment of guidelines. So all the hard work that we've been doing over many years, it's getting to the pointy end because that's where that's to us the trigger point. We are selling some trophons over there at the moment. but we need those guidelines in place to reach a point of inflection. And in Japan, it's one of those markets where we're investing in the cost traditionally, it can be the third, fourth individual largest market outside of the United States. And on the population basis in Japan, there's more ultrasound procedures done per capita than anywhere in the world. So it's work, it's the effort. As an organization, we have to make strategic bets. We discussed that at the Board and we think Japan is one of those. But the great news is, we believe, guidelines, the appropriate mechanisms for guidelines establishment now are underway.

Matthew Carbines executive
#46

We do have a few more questions. I got but perhaps we have time for a couple more. Yes, maybe 2 or -- so the next one is about the trophon only P&L and the shareholder understands that this excludes CORIS costs but does it include the general corporate costs in that trend?

Michael Kavanagh executive
#47

Yes. So the trophon only business includes all the corporate costs. So even though I would say percentage of my time, all the executive's time, the overheads associated with the buildings, et cetera, have a forest component to it. all of those costs are captured in the trophon only business, which again, I think, signifies the performance of that business has been a profit profit cash-generating business, which we're looking to emulate again with CORIS.

Matthew Carbines executive
#48

And if we had time for 2 more, this would be the last one, which is a long question relating to the shorts on the stock that has been experienced. And the question is, can we share everything we know and summarizing it. Can we share everything we know about the shorts? And in particular, do we know whether our major shareholders have a policy of lending their stock to the shorts?

Michael Kavanagh executive
#49

The shorts pleasingly have gone down about 50% in the last 12 months. It's not the favorite part of my -- I come to work every day to try and grow and to have people out there looking to hope almost for something to go down for financial gain is just against one of my principles. And sorry, that's probably a thought verbalized. But in terms of the thesis that some of the shorts have, I mean, it's a financial instrument. A lot of these, the many funds leverage and use and we have no control over it. The only thing I would say in the short is as long as we keep executing. Well, then that's our job, keep executing against our strategy and our priorities to take to buy the strategy, but then the shorts really don't have much like system for the future. But they are coming down.

Steven Sargent executive
#50

Thank you for that. I think we've covered off all of those. And so that concludes business today of the meeting, and I declare the meeting closed. Thank you very much for joining us today. It's always great to see you, and we really do appreciate your support that you've given the company over a very long period of time. Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nanosonics Limited transcript - plus 261,000+ transcripts from 13,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Nanosonics Limited earnings transcripts and 261,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $145 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.